
Overview
Poltreg is a company that specializes in Treg autoimmune therapy, focusing on developing cell therapies for autoimmune diseases. It has a pipeline that includes PTG007, a potential treatment for Type-1 Diabetes and Multiple Sclerosis, and is working on launching in-patient trials for CAR-Tregs in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. The company also boasts world-class manufacturing capabilities and aims to bring Treg therapies to routine use as disease-modifying therapeutics.
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2023, 1 day late). All were audited by a statutory auditor.
- 202523/06/2026
- 202403/06/2025
- 202316/07/2024
- 202228/06/2023
- 202111/07/2022
- 202007/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 18.95
- High
- PLN 18.95
- Low
- PLN 18.55
- Volume
- 201
- Avg. vol.
- 4.47K
- Market cap
- PLN 109.75M
- P/E ratio
- –
- EPS
- -PLN 4.13
- Shares outstanding
- 5.92M
- 52-week
- PLN 18.00 – 21.70
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLPLTRG00038
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 64.83k | USD -1.50m | USD -1.53m |
| Q1 2026 | USD 67.53k | USD -1.77m | USD -1.83m |
| Q4 2025 | USD 25.11k | USD -1.50m | USD -1.50m |
| Q3 2025 | USD 50.23k | USD -1.52m | USD -1.52m |
Results for Q3 2026:Nov 18, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Parexel to support PolTREG's European registration of the world's first Treg cell therapy for type 1 diabetes
GDAŃSK, Poland, July 31, 2026 – PolTREG S.A. (WSE: PTG), one of the global pioneers in Treg cell therapies, has entered into an agreement with Parexel International (IRL) Limited to support the preparation and submission of its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for PTG-007.

Prof. Piotr Trzonkowski co-authored a prestigious publication in Frontiers in Science with a Nobel Prize winner
The prestigious journal Frontiers in Science has published a review article, “Regulatory T cells: master orchestrators of immune tolerance and tissue homeostasis,” co-authored by Prof. Piotr Trzonkowski, President of the Management Board and Chief Scientific Officer of PolTREG SA. The article was prepared by a group of world leaders in regulatory T cell (Treg) research, including Dr. Frederick J. Ramsdell, winner of the 2025 Nobel Prize in Physiology or Medicine.

Dr. Michael Rosenblum, leading University of California (UCSF) immunologist and dermatologist appointed to Immuthera Scientific Advisory Board
June 1, 2026 – Immuthera, the USA subsidiary of PolTREG S.A., an emerging leader in engineered T regulatory (CAR-Treg) cell therapies, today announced the appointment of renowned dermatologist and immunologist Michael Rosenblum, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Rosenblum will help guide the clinical advancement of Immuthera’s first-in-class CD6/CTLA4 CAR-Treg platform as it relates to the development of this therapy in severe dermatological and related autoimmune and…

PolTREG summarizes 2025 – the way to registration in Europe of the world's first TREG therapy for diabetes begins
PolTREG SA, a global leader in the development of therapies using T-regulatory T cells (TREGS), summarized 2025 and presented key milestones for 2026. The company has unique data on a global scale confirming the 12-year effectiveness of TREG therapy in the treatment of diabetes and is preparing to submit an application to the European Medicines Agency (EMA) for central marketing authorization for the therapy in the European Union.

PolTREG has completed the ABB process and will obtain funds to finance key projects with the highest therapeutic and commercial potential
This material is for informational purposes only and does not constitute an offer, nor is it made available, to promote, directly or indirectly, the purchase or acquisition of PolTREG SA securities, or to encourage, directly or indirectly, the purchase or acquisition of such securities. This report does not constitute advertising or promotional material prepared or published by PolTREG SA for the purpose of promoting the shares, their subscription, purchase, or offering, or to encourage…

PolTREG at Life Science Investor Day
On March 11 , representatives of PolTREG S.A. will take part in Life Science Investor Day , organized by Strefa Inwestorów , to discuss the outlook for the biotech sector and the company’s development plans.
Industry
Offer
- Cell therapies
- Regulatory T-cell therapies
- Autoimmune disease therapies
- Clinical trials
Websites
The site is available in: Polish and English.
- poltreg.bioPoltreg – The future of medicineWordPress 7.1WWPMLCloudflare
Public procurement
1 tender recorded as contractor, with a total value of $2,712,205.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Feb 18, 2025 | 145/WR/2024 - Provision of medical services involving the manufacture of a Treg lymphocyte preparation, an advanced therapy medicinal product for the treatment of patients with type 1 diabetes, for UCK | $2.7M$2,712,205 | Uniwersyteckie Centrum Kliniczne |
Job offers
The company lists 2 job openings on its own careers page: poltreg.bio/career.
Authorized Representatives
Manner of representation
If the management board consists of two or more members, each member of the management board is entitled to make declarations on behalf of the company independently. However, in property matters with a value exceeding PLN 50,000.00 (fifty thousand zlotys and zero groszy), joint action by two members of the management board is required to make declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2015-07-03.
54 1050 1764 1000 0090 8474 2536
60 1050 1764 1000 0090 3063 3888
04 1050 1764 1000 0090 8651 0097
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 26, 2021 | Bankruptcy notice | |
| Jan 29, 2021 | Commercial Companies Code notice | |
| Jan 20, 2021 | Liquidation opened | |
| Feb 25, 2019 | Commercial Companies Code notice |
Public aid
20 public aid cases recorded, with a total value of $16,077,740.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 30, 2026 | Aid for research and development projects: industrial research | $336.4K$336,402 | Prezes Agencji Badań Medycznych | |
| Apr 22, 2025 | Aid for research and development projects: industrial research | $1.4M$1,385,944 | Prezes Agencji Badań Medycznych | |
| Apr 22, 2025 | Aid for research and development projects: experimental development | $174.6K$174,604 | Prezes Agencji Badań Medycznych |
European Funds
7 projects recorded: 3 from FE lists ($4,536,644) and 4 Commission grants (FTS) ($3,875,338).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-05-26 | Next generations of cell therapies in autoimmunology | $1.2M$1,185,343 | European Funds for Pomerania 2021-2027 | |
| 2023-07-01 | Autoantigen-specific adoptive regulatory t cell therapy against type 1 diabetes (artide) | $450.3K$450,337 | 1.0.11 - Horizon Europe | |
| 2023-07-01 | Autoantigen-specific adoptive regulatory t cell therapy against type 1 diabetes (artide) | $421.3K$421,283 | 1.0.11 - Horizon Europe |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Ryvu Therapeutics S.A. | $25,867,403.31 | ryvu.com | ||
| Aronpharma sp. z o.o. | $3,197,864.33 | aronpharma.pl | ||
| Biotechna S.A. | $2,472,888.07 | bsbiotechna.com | ||
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| SDS Optic S.A. | $1,374,353.92 | sdsoptic.pl | ||
| Fileclo sp. z o.o. | $722,197.66 | fileclo.pl | ||
| Bioceltix S.A. | $616,315.97 | bioceltix.com | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| Multiqure S.A. | $284,781.52 | purebiologics.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-04-16 | Share capital increase (466,344.80 PLN → 591,645.60 PLN) | |
| 2023-03-24 | Address change (Ul. Wały Piastowskie 1/1508, 80-855, Gdańsk → Ul. Botaniczna 20, 80-298, Gdańsk) | |
| 2021-12-09 | Share capital increase (333,103.40 PLN → 466,344.80 PLN) | |
| 2020-12-23 | Share capital increase (299,853.40 PLN → 333,103.40 PLN) | |
| 2020-07-29 | Share capital increase (215,276.20 PLN → 299,853.40 PLN) |
FAQ
Last updated: 2026-08-07